Outcome of Stem Cell Transplantation from Low resources set up Bone Marrow Transplantation unit
Keywords:
Stem Cell Transplantation, Low resources set up Bone Marrow TransplantationAbstract
In Thailand, despite the improvement of care for malignancies, some groups of patients have failed to respond to standard treatment and faced recurrence of diseases. Thailand is an endemic area of several genetic disorders and thalassemia has been a budgetary burden for the Royal Thai government.
Hematopoietic stem cell transplantation (HSCT) is a definite cure for several hematological diseases including malignancies, thalassemia and severe aplastic anemia. Bone marrow transplantation (BMT) was found promising in spite of low resources. Thirteen cases of BMT (10 cases for autologous and 3 cases for allogeneic transplantations) were performed and outstanding outcomes were reported in this study. The median follow-up time was 11 months (2 months – 47 months range). Both disease-free survival and overall survival were 100% with 10 months median disease-free survival time. One case had acute GVHD grade I with no evidence of chronic GVHD. Moreover, the median cost of autologous BMT was US$10,601 dollars (US$7,113 – 14,872 range) and the median cost of allogeneic BMT was US$ 15,153 dollars (US$ 13,808 – 16,924 range) which were more economical than the BMT costs in the developed countries. Maintaining basic necessities such as HEPA filter system with positive pressure gradients room air and lab checkup as much as necessary can both reduce expenses and prevent complications.
References
Kellie SJ, Howard SC. Global child health priorities: what role for paediatric oncologists? Eur J Cancer. 2008 Nov; 44(16):2388-96. Doi: 10.1016/j.ejca. 2008.07.022. Epub 2008 Sep 15. Review. PubMed PMID: 18799306.
Tienthavorn V, Patrakulvanish S, Pattanapongthorn J, Voramongkol N, Sanguansermsri T, Charoenkwan P: Prevalence of thalassemia carrier and risk of spouse to have a severe thalassemic child in Thailand. In National Conference on Thalassemia 11st; Miracle Grand Hotel, Bangkok. Department of Health, Ministry of Public Health, Thalassemia Foundation of Thailand; 2005.
Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010 Jun 3; 115 (22):4331-6. Doi: 10.1182/blood-2010-01-251348. Epub 2010 Mar 16. Review. PubMed PMID: 20233970; PubMed Central PMCID: PMC2881491.
Ho WL, Lin KH, Wang JD, Hwang JS, Chung CW, Lin DT, Jou ST, Lu MY, Chern JP. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant. 2006 Mar; 37(6):569-74. PubMed PMID: 16462756.
Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011 Sep 29;118(13): 3479-88. Doi: 10.1182/blood-2010-08-300335. Epub 2011 Aug 2. Review. PubMed PMID: 21813448.
Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U, et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant. 2006; 12:683-7.
Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Sura T, Ungkanont A, et al. Reduced intensity stem cell transplantation for treatment of class 3 Lucarelli severe thalassemia patients. Am J Hematol. 2007; 82:1095-8.
Lee SJ, Klar N, Weeks JC, Antin JH. Predicting costs of stem-cell transplantation. J Clin Oncol. 2000 Jan; 18(1):64-71. PubMed PMID: 10623694.
Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer. 2008 Mar 1;112(5):1096-105. Doi: 0.1002/cncr.23281. PubMed PMID: 18286506.
Faucher C, Le Corroller Soriano AG, Esterni B, Vey N, Stoppa AM, Chabannon C, et al. Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant. 2012 Apr; 47(4):549-55. Doi: 10.1038/bmt.2011.126.Epub 2011 Jul 4. PubMed PMID: 21725375.
Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant. 2005 Oct; 36(7):649-54. PubMed PMID: 16044135.
Sharma SK, Choudhary D, Gupta N, Dhamija M, Khandelwal V, Kharya G, et al. Cost of hematopoietic stem cell transplantation in India. Mediterr J Hematol Infect Dis. 2014; 6:e2014046.
Ngamkiatphaisan S, Sriratanaban J, Kamolratanakul P, Intragumtornchai T, Noppakun N, Jongudomsuk P. Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 2007 Dec; 90(12):2565-73. PubMed PMID: 18386705.
Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011; 117:1745-50.
Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:456-62.
Caocci G, Efficace F, Ciotti F, Roncarolo MG, Vacca A, Piras E, et al. Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation [abstract]. Biol Blood Marrow Transplant [online] 2011 [cite 2017 Feb 15]; 17(6):861-6. Available from : http://www.ncbi.nlm.nih.gov/pubmed/20870029.
Cheuk DK, Mok AS, Lee AC, Chiang AK, Ha SY, Lau YL, et al. Quality of life in patients with transfusiondependent thalassemia after hematopoietic SCT. Bone Marrow Transplant. 2008;42:319-27.
Riewpaiboon A, Nuchprayoon I, Torcharus K, Indaratna K, Thavorncharoensap M, Ubol BO. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3:29.
Kumar R, Naithani R, Mishra P, Mahapatra M, Seth T, Dolai TK, et al. Allogeneic hematopoietic SCT performed in non-HEPA filter rooms: initial experience from a single center in India. Bone Marrow Transplant. 2009; 43:115-9.
Khera N, Zeliadt SB, Lee SJ. Economics of hematopoietic cell transplantation. Blood. [Online] 2012 [cite 2017 Feb 25]; 8:[7screens]. Available from: http://dx.doi.org/10.1182/blood-2012-05-426783.
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb;14(2):197-207. Doi: 10.1016/j.bbmt.2007.10.010. PubMed PMID: 18215780; PubMed Central PMCID: PMC2259445.
Espérou H, Brunot A, Roudot-Thoraval F, Buzyn A, Dhedin N, Rio B, et al. Predicting the costs of allogeneic sibling stem-cell transplantation: results from a prospective, multicenter, French study. Transplantation. 2004 Jun 27;77(12):1854- 8. PubMed PMID: 15223903.
Chandy M. Stem cell transplantation in India. Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S81-S84. Doi: 10.1038/bmt.2008.124. Review. PubMed PMID: 18724312.
Mukhopadhyay A, Gupta P, Basak J, Chakraborty A, Bhattacharyya D, Mukhopadhyay S, et al. Stem cell transplant: An experience from eastern India. Indian J Med Paediatr Oncol. 2012 Oct;33(4):203- 9. Doi: 10.4103/0971-5851.107078. PubMed PMID: 23580820; PubMed Central PMCID: PMC3618641.
Leelahavarong P, Chaikledkaew U, Hongeng S, Kasemsup V, Lubell Y, Teerawattananon Y. A cost-utility and budget impact analysis of allogeneichematopoieticstemcelltransplantation for severe thalassemic patients in Thailand. BMC Health Serv Res. 2010;10:209.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Journal of Department of Health Service Support-วารสารวิชาการกรมสนับสนุนบริการสุขภาพ
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.